Seer (NASDAQ:SEER – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Seer and Amicus Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seer | 1 | 0 | 0 | 0 | 1.00 |
| Amicus Therapeutics | 1 | 9 | 3 | 0 | 2.15 |
Amicus Therapeutics has a consensus target price of $15.39, indicating a potential upside of 6.35%. Given Amicus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Seer.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seer | $16.58 million | 5.75 | -$73.60 million | ($1.28) | -1.32 |
| Amicus Therapeutics | $634.21 million | 7.16 | -$27.11 million | ($0.08) | -180.88 |
Amicus Therapeutics has higher revenue and earnings than Seer. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Seer has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
Profitability
This table compares Seer and Amicus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seer | -443.96% | -26.04% | -23.10% |
| Amicus Therapeutics | -4.27% | 4.15% | 1.09% |
Insider & Institutional Ownership
75.2% of Seer shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Amicus Therapeutics beats Seer on 10 of the 14 factors compared between the two stocks.
About Seer
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
